With No Lysine Kinase 3 (WNK3); A Target Enabling Package von Pinkas, D

Weitere Verfasser: “… Pinkas, D …”

With no lysine kinase 3 (WNK3); A Target Enabling Package von Pinkas, D

Weitere Verfasser: “… Pinkas, D …”

Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors von Suebsuwong, C, Pinkas, D, Ray, S, Bufton, J, Dai, B, Bullock, A, Degterev, A, Cuny, G

2-amino-2, 3-dihydro-1H-indene-5-carboxamide-based discoidin domain receptors 1 (DDR1) inhibitors: design, synthesis, and in vivo anti-pancreatic cancer efficacy von Zhu, D, Huang, H, Pinkas, D, Luo, J, Ganguly, D, Fox, A, Arner, E, Xiang, Q, Tu, Z, Bullock, A, Brekken, R, Ding, K, Lu, X

BTB domain mutations perturbing KCTD15 oligomerisation cause a distinctive frontonasal dysplasia syndrome von Miller, K, Cruz Walma, D, Pinkas, D, Tooze, R, Bufton, J, Richardson, W, Manning, C, Hunt, A, Cros, J, McGowan, S, Twigg, S, Chalk, R, Staunton, D, Johnson, D, Wilkie, A, Bullock, A

The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms von Fulcher, L, Bozatzi, P, Tachie-Menson, T, Wu, K, Cummins, T, Bufton, J, Pinkas, D, Dunbar, K, Shrestha, S, Wood, N, Weidlich, S, Macartney, T, Varghese, J, Gourlay, R, Campbell, D, Dingwell, K, Smith, J, Bullock, A, Sapkota, G

Design, synthesis, and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a dua... von Wang, Z, Zhang, Y, Pinkas, D, Fox, A, Luo, J, Huang, H, Cui, S, Xiang, Q, Xu, T, Xun, Q, Zhu, D, Tu, Z, Ren, X, Brekken, R, Bullock, A, Liang, G, Ding, K, Lu, X

With No Lysine Kinase 3 (WNK3); A Target Enabling Package von Bullock, A

Weitere Verfasser: “… Pinkas, D …”